US health care major Johnson & Johnson says that all applicable foreign antitrust and similar regulatory clearances required for its cash tender offer to purchase USA-based Mentor Corp have been obtained (Marketletter December 8, 2008).
Late last year, J&J agreed to acquire cosmetic-product and breast-implant maker Mentor for $1.07 billion. Mentor is expected to operate as a stand-alone business unit reporting through J&J unit Ethicon, a leading provider of suture, mesh and other products for a wide range of surgical procedures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze